Aspirin does not prevent recurrence after treatment for colorectal cancer liver metastases
Colorectal cancer is one of the most common cancers in Norway, which also has one of the highest incidence rates in the world.
A new study published in The Lancet Gastroenterology & Hepatology has found that aspirin does not prevent colorectal cancer from recurring after treatment of liver metastases. Researchers conducted a randomized, double-blind trial involving 466 patients who had undergone treatment for colorectal cancer liver metastases at 14 hospitals across Norway, Sweden, and Denmark.
The patients were randomly assigned to receive either aspirin 160 mg daily or a placebo for up to three years. The study found that patients taking aspirin had the same risk of recurrence as those taking placebo, and the aspirin group experienced a higher overall mortality rate and more serious adverse events. The researchers concluded that aspirin should not be routinely recommended to prevent recurrence in this population, as the results did not show any benefit and raised concerns about potential harms.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
